Recombinant Anti-HER2 x Anti-VEGF Bispecific Antibody (Tandem scFv) is designed to be expressed as a scFv from an anti-HER2 antibody variable domains fused with a scFv from an anti-VEGF antibody variable domains. It contains a His-tag at the C/N terminus for affinity purification. The BsAb exits as monomer in reducing and non-reducing conditions. This BsAb can bind two factors simultaneously and inhibit cell proliferation. It is designed for the research of Colorectal cancer; Breast cancer; Lung cancer; Renal cell cancer (RCC); Glioma cancer; Glioblastoma; Ovarian cancer therapy.